Cyclodextrin-based polymers for therapeutics delivery
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-047/48
C08B-037/16
C08F-224/00
C08G-063/91
출원번호
US-0739896
(2013-01-11)
등록번호
US-8609081
(2013-12-17)
발명자
/ 주소
Cheng, Jianjun
Davis, Mark E.
Khin, Kay T.
출원인 / 주소
Cerulean Pharma Inc.
대리인 / 주소
Lando & Anastasi LLP
인용정보
피인용 횟수 :
0인용 특허 :
123
초록▼
The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and red
The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.
대표청구항▼
1. A pharmaceutical composition comprising a sugar and a water soluble linear polymer conjugate, wherein the water soluble linear polymer conjugate comprises: a linear polymer comprising cyclodextrin moieties and comonomers which do not contain cyclodextrin moieties (comonomers); andtherapeutic agen
1. A pharmaceutical composition comprising a sugar and a water soluble linear polymer conjugate, wherein the water soluble linear polymer conjugate comprises: a linear polymer comprising cyclodextrin moieties and comonomers which do not contain cyclodextrin moieties (comonomers); andtherapeutic agents covalently linked to the linear polymer, wherein the therapeutic agents are poorly soluble in water and are cleaved from the water soluble linear polymer conjugate under biological conditions to release the therapeutic agents;wherein the water soluble linear polymer conjugate comprises at least four cyclodextrin moieties and at least four comonomers. 2. The pharmaceutical composition of claim 1, wherein each of the at least four cyclodextrin moieties and each of the at least four comonomers alternate in the water soluble linear polymer conjugate. 3. The pharmaceutical composition of claim 1, wherein the therapeutic agents are attached via linkers. 4. The pharmaceutical composition of claim 1, wherein the comonomer comprises residues of at least two functional groups through which reaction and linkage of the cyclodextrin moieties was achieved. 5. The pharmaceutical composition of claim 4, wherein the at least two functional groups, which may be the same or different, or terminal or internal, of each comonomer comprise an amino acid, imidazole, hydroxyl, thio, acyl halide, —HC═CH—, —C≡C— group, or derivative thereof. 6. The pharmaceutical composition of claim 1, wherein the cyclodextrin moiety comprises an alpha, beta, or gamma cyclodextrin moiety. 7. The pharmaceutical composition of claim 1, wherein the therapeutic agent is at least 5% by weight of the water soluble linear polymer conjugate. 8. The pharmaceutical composition of claim 1, wherein the comonomers comprise polyethylene glycol and the cyclodextrin moieties comprises beta-cyclodextrin. 9. The pharmaceutical composition of claim 1, wherein the therapeutic agent is an inhibitor of the S phase of the cell cycle. 10. The pharmaceutical composition of claim 1, wherein the therapeutic agent is doxorubicin. 11. The pharmaceutical composition of claim 1, wherein the therapeutic agent is an antifungal. 12. The pharmaceutical composition of claim 1, wherein administration of the composition to a patient results in release of the therapeutic agent over a period of at least 6 hours. 13. The pharmaceutical composition of claim 1, wherein administration of the composition to a patient results in release of the therapeutic agent over a period of 6 hours to a month. 14. The pharmaceutical composition of claim 1, wherein, upon administration of the composition to a patient the rate of therapeutic agent release is dependent primarily upon the rate of hydrolysis as opposed to enzymatic cleavage. 15. The pharmaceutical composition of claim 1, wherein the water soluble linear polymer conjugate has a molecular weight of 10,000-500,000 amu. 16. The pharmaceutical composition of claim 1, wherein the cyclodextrin moieties make up at least about 10% of the linear polymer by weight. 17. The pharmaceutical composition of claim 1, wherein the comonomer comprises: an alkylene chain,polysuccinic anhydride,poly-L-glutamic acid,poly(ethyleneimine),an oligosaccharide, oran amino acid chain. 18. The pharmaceutical composition of claim 1, wherein the comonomers comprise polyethylene glycol. 19. The pharmaceutical composition of claim 1, wherein the comonomers comprise polyglycolic acid or polylactic acid. 20. The pharmaceutical composition of claim 1, wherein the comonomer comprises a hydrocarbylene group wherein one or more methylene groups is optionally replaced by a group Y (provided that none of the Y groups are adjacent to each other), wherein each Y, independently for each occurrence, is selected from, substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or —O—, C(═X) (wherein X is NR1, O or S), —OC(O)—, —C(═O)O, —NR1—, —NR1CO—, —C(O)NR1—, —S(O)n— (wherein n is 0, 1, or 2), —OC(O)—NR1, —NR1—C(O)—NR1—, —NR11-C(NR1)—NR1—, and —B(OR1)—; and R1, independently for each occurrence, represents H or a lower alkyl. 21. The pharmaceutical composition of claim 1 further comprising a pharmaceutical excipient. 22. The pharmaceutical composition of claim 8 further comprising a pharmaceutical excipient. 23. The pharmaceutical composition of claim 9 further comprising a pharmaceutical excipient. 24. The pharmaceutical composition of claim 1, wherein the sugar is mannitol. 25. The pharmaceutical composition of claim 8, wherein the sugar is mannitol. 26. The pharmaceutical composition of claim 1, wherein the solubility of the therapeutic agent is 0.4, >0.6, >0.8, >1, >2, >3, >4, or >5. 28. The pharmaceutical composition of claim 1, wherein the therapeutic agent is hydrophobic and is attached via a second compound. 29. The pharmaceutical composition of claim 3, wherein the linker comprises a plurality of amino acids. 30. The pharmaceutical composition of claim 3, wherein the linker is a dipeptide. 31. The pharmaceutical composition of claim 3, wherein the linker is glycine. 32. The pharmaceutical composition of claim 6, wherein the cyclodextrin moiety comprises beta cyclodextrin. 33. The pharmaceutical composition of claim 1, wherein the therapeutic agent is at least 10% by weight of the water soluble linear polymer conjugate. 34. The pharmaceutical composition of claim 1, wherein the therapeutic agent is at least 15% by weight of the water soluble linear polymer conjugate. 35. The pharmaceutical composition of claim 1, wherein the therapeutic agent is at least 20% by weight of the water soluble linear polymer conjugate. 36. The pharmaceutical composition of claim 1, wherein the therapeutic agent is at least 25% by weight of the water soluble linear polymer conjugate. 37. The pharmaceutical composition of claim 1, wherein the water soluble linear polymer conjugate has a molecular weight of 30,000-520,000 amu. 38. The pharmaceutical composition of claim 1, wherein the water soluble linear polymer conjugate has a molecular weight of 70,000-150,000 amu. 39. The pharmaceutical composition of claim 1, wherein the cyclodextrin moieties make up at least about 2% of the polymer by weight. 40. The pharmaceutical composition of claim 1, wherein the cyclodextrin moieties make up at least about 5% of the polymer by weight. 41. The pharmaceutical composition of claim 1, wherein the cyclodextrin moieties make up at least about 20% of the polymer by weight. 42. The pharmaceutical composition of claim 1, wherein the cyclodextrin moieties make up at least about 30% of the polymer by weight. 43. The pharmaceutical composition of claim 18, wherein the polyethylene glycol has a molecular weight of 0.2 kDa to 5 kDa. 44. A pharmaceutical composition comprising a sugar and a water soluble linear polymer conjugate, wherein the water soluble linear polymer conjugate comprises: a linear polymer comprising cyclodextrin moieties and comonomers which do not contain cyclodextrin moieties (comonomers); andtherapeutic agents covalently linked to the linear polymer, wherein the therapeutic agents are cleaved from the water soluble linear polymer conjugate under biological conditions to release the therapeutic agents;wherein the water soluble linear polymer conjugate comprises at least four cyclodextrin moieties and at least four comonomers, and the sugar is selected from lactose, glucose, sucrose or sorbitol. 45. The pharmaceutical composition of claim 44, wherein each of the at least four cyclodextrin moieties and each of the at least four comonomers alternate in the water soluble linear polymer conjugate. 46. The pharmaceutical composition of claim 44, wherein the therapeutic agents are attached via linkers. 47. The pharmaceutical composition of claim 46, wherein the linker comprises an amino acid. 48. The pharmaceutical composition of claim 46, wherein the linker comprises a plurality of amino acids. 49. The pharmaceutical composition of claim 46, wherein the linker is a dipeptide. 50. The pharmaceutical composition of claim 46, wherein the linker is glycine. 51. The pharmaceutical composition of claim 44, wherein the comonomer comprises residues of at least two functional groups through which reaction and linkage of the cyclodextrin moieties was achieved. 52. The pharmaceutical composition of claim 51, wherein the at least two functional groups, which may be the same or different, or terminal or internal, of each comonomer comprise an amino acid, imidazole, hydroxyl, thio, acyl halide, —HC═CH—, —C≡C— group, or derivative thereof. 53. The pharmaceutical composition of claim 44, wherein the cyclodextrin moiety comprises an alpha, beta, or gamma cyclodextrin moiety. 54. The pharmaceutical composition of claim 53, wherein the cyclodextrin moiety comprises a beta cyclodextrin moiety. 55. The pharmaceutical composition of claim 44, wherein the therapeutic agent is at least 5% by weight of the water soluble linear polymer conjugate. 56. The pharmaceutical composition of claim 44, wherein the therapeutic agent is at least 10% by weight of the water soluble linear polymer conjugate. 57. The pharmaceutical composition of claim 44, wherein the therapeutic agent is at least 15% by weight of the water soluble linear polymer conjugate. 58. The pharmaceutical composition of claim 44, wherein the therapeutic agent is at least 20% by weight of the water soluble linear polymer conjugate. 59. The pharmaceutical composition of claim 44, wherein the therapeutic agent is at least 25% by weight of the water soluble linear polymer conjugate. 60. The pharmaceutical composition of claim 44, wherein the comonomers comprise polyethylene glycol and the cyclodextrin moieties comprise beta-cyclodextrin. 61. The pharmaceutical composition of claim 44, wherein the therapeutic agent is an anti-neoplastic agent. 62. The pharmaceutical composition of claim 44, wherein the therapeutic agent is an inhibitor of the S phase of the cell cycle. 63. The pharmaceutical composition of claim 44, wherein the therapeutic agent is a topoisomerase I inhibitor. 64. The pharmaceutical composition of claim 44, wherein the therapeutic agent is doxorubicin. 65. The pharmaceutical composition of claim 44, wherein the therapeutic agent is an antifungal. 66. The pharmaceutical composition of claim 44, wherein the therapeutic agent is a camptothecin analog. 67. The pharmaceutical composition of claim 66, wherein the camptothecin analog is topotecan. 68. The pharmaceutical composition of claim 66, wherein the camptothecin analog is irinotecan. 69. The pharmaceutical composition of claim 44, wherein the therapeutic agent is a peptide. 70. The pharmaceutical composition of claim 44, wherein the therapeutic agent is an anti-inflammatory agent. 71. The pharmaceutical composition of claim 44, wherein administration of the composition to a patient results in release of the therapeutic agent over a period of at least 6 hours. 72. The pharmaceutical composition of claim 44, wherein administration of the composition to a patient results in release of the therapeutic agent over a period of 6 hours to a month. 73. The pharmaceutical composition of claim 44, wherein, upon administration of the composition to a patient the rate of therapeutic agent release is dependent primarily upon the rate of hydrolysis as opposed to enzymatic cleavage. 74. The pharmaceutical composition of claim 44, wherein the water soluble linear polymer conjugate has a molecular weight of 10,000-500,000 amu. 75. The pharmaceutical composition of claim 44, wherein the water soluble linear polymer conjugate has a molecular weight of 30,000-520,000 amu. 76. The pharmaceutical composition of claim 44, wherein the water soluble linear polymer conjugate has a molecular weight of 70,000-150,000 amu. 77. The pharmaceutical composition of claim 44, wherein the cyclodextrin moieties make up at least about 10% of the linear polymer by weight. 78. The pharmaceutical composition of claim 44, wherein the cyclodextrin moieties make up at least about 2% of the polymer by weight. 79. The pharmaceutical composition of claim 44, wherein the cyclodextrin moieties make up at least about 5% of the polymer by weight. 80. The pharmaceutical composition of claim 44, wherein the cyclodextrin moieties make up at least about 20% of the polymer by weight. 81. The pharmaceutical composition of claim 44, wherein the cyclodextrin moieties make up at least about 30% of the polymer by weight. 82. The pharmaceutical composition of claim 44, wherein the comonomers comprise: an alkylene chain,polysuccinic anhydride,poly-L-glutamic acid,poly(ethyleneimine),an oligosaccharide, oran amino acid chain. 83. The pharmaceutical composition of claim 44, wherein the comonomers comprise polyethylene glycol. 84. The pharmaceutical composition of claim 83, wherein the polyethylene glycol has a molecular weight of 0.2 kDa to 5 kDa. 85. The pharmaceutical composition of claim 44, wherein the comonomers comprise polyglycolic acid or polylactic acid chain. 86. The pharmaceutical composition of claim 44, wherein the comonomer comprises a hydrocarbylene group wherein one or more methylene groups is optionally replaced by a group Y (provided that none of the Y groups are adjacent to each other), wherein each Y, independently for each occurrence, is selected from, substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or —O—, C(═X) (wherein X is NR1, O or S), —OC(O)—, —C(═O)O, —NR1—, —NR1CO—, —C(O)NR1—, —S(O)n— (wherein n is 0, 1, or 2), —OC(O)—NR1, —NR1—C(O)—NR1—, —NR11-C(NR1)—NR1—, and —B(OR1)—; and R1, independently for each occurrence, represents H or a lower alkyl. 87. The pharmaceutical composition of claim 44 further comprising a pharmaceutical excipient. 88. A pharmaceutical composition comprising a sugar and a polymer having attached thereto a plurality of D moieties of the following formula: wherein each L is independently a linker, and each D is independently a therapeutic agent, a prodrug derivative thereof, or absent; andwherein the group has a Mw of 0.2 to 5 kDa and n is at least 4, provided that the polymer comprises at least one therapeutic agent, or prodrug derivative thereof. 89. The pharmaceutical composition of claim 88, wherein each L of the polymer independently comprises an amino acid or a derivative thereof. 90. The pharmaceutical composition of claim 88, wherein each L of the polymer independently comprises a plurality of amino acids or derivatives thereof. 91. The pharmaceutical composition of claim 88, wherein each L of the polymer is independently a dipeptide or derivative thereof. 92. The pharmaceutical composition of claim 88, wherein the therapeutic agent is an anti-neoplastic agent. 93. The pharmaceutical composition of claim 88, wherein the therapeutic agent is an inhibitor of the S phase of the cell cycle. 94. The pharmaceutical composition of claim 88, wherein the therapeutic agent is a topoisomerase I inhibitor. 95. The pharmaceutical composition of claim 88, wherein the therapeutic agent is doxorubicin. 96. The pharmaceutical composition of claim 88, wherein the therapeutic agent is an antifungal. 97. The pharmaceutical composition of claim 88, wherein the therapeutic agent is a camptothecin analog. 98. The pharmaceutical composition of claim 97, wherein the camptothecin analog is topotecan. 99. The pharmaceutical composition of claim 97, wherein the camptothecin analog is irinotecan. 100. The pharmaceutical composition of claim 88, wherein the therapeutic agent is a peptide. 101. The pharmaceutical composition of claim 88, wherein the therapeutic agent is an anti-inflammatory agent. 102. The pharmaceutical composition of claim 88, wherein the sugar is mannitol, lactose, glucose, sucrose or sorbitol. 103. The pharmaceutical composition of claim 88 further comprising a pharmaceutical excipient. 104. A pharmaceutical composition comprising a sugar and a polymer having attached thereto a plurality of L-D moieties of the following formula: wherein each L is independently a linker or absent and each D is independently a therapeutic agent, a prodrug derivative thereof, or —OH and wherein the group has a Mw of 0.2 to 5 kDa and n is at least 4, provided that the polymer comprises at least one therapeutic agent, or prodrug derivative thereof. 105. The pharmaceutical composition of claim 104, wherein each L of the polymer independently comprises an amino acid or derivative thereof. 106. The pharmaceutical composition of claim 104, wherein the therapeutic agent is an anti-neoplastic agent. 107. The pharmaceutical composition of claim 104, wherein the therapeutic agent is an inhibitor of the S phase of the cell cycle. 108. The pharmaceutical composition of claim 104, wherein the therapeutic agent is a topoisomerase I inhibitor. 109. The pharmaceutical composition of claim 104, wherein the therapeutic agent is doxorubicin. 110. The pharmaceutical composition of claim 104, wherein the therapeutic agent is an antifungal. 111. The pharmaceutical composition of claim 104, wherein the therapeutic agent is a camptothecin analog. 112. The pharmaceutical composition of claim 111, wherein the camptothecin analog is topotecan. 113. The pharmaceutical composition of claim 111, wherein the camptothecin analog is irinotecan. 114. The pharmaceutical composition of claim 104, wherein the therapeutic agent is a peptide. 115. The pharmaceutical composition of claim 104, wherein the therapeutic agent is an anti-inflammatory agent. 116. The pharmaceutical composition of claim 104, wherein the sugar is mannitol, lactose, glucose, sucrose or sorbitol. 117. The pharmaceutical composition of claim 104 further comprising a pharmaceutical excipient. 118. The pharmaceutical composition of claim 1, wherein the sugar is lactose, glucose, sucrose or sorbitol. 119. The pharmaceutical composition of claim 8, wherein the sugar is lactose, glucose, sucrose or sorbitol. 120. The pharmaceutical composition of claim 9, wherein the sugar is mannitol. 121. The pharmaceutical composition of claim 9, wherein the sugar is lactose, glucose, sucrose or sorbitol. 122. The pharmaceutical composition of claim 3, wherein the linker comprises an amino acid. 123. The pharmaceutical composition of claim 104, wherein each L of the polymer is glycine or a derivative thereof. 124. The pharmaceutical composition of claim 18, wherein each of the at least four cyclodextrin moieties and each of the at least four comonomers alternate in the water soluble linear polymer conjugate. 125. The pharmaceutical composition of claim 43, wherein each of the at least four cyclodextrin moieties and each of the at least four comonomers alternate in the water soluble linear polymer conjugate. 126. The pharmaceutical composition of claim 83, wherein each of the at least four cyclodextrin moieties and each of the at least four comonomers alternate in the water soluble linear polymer conjugate. 127. The pharmaceutical composition of claim 84, wherein each of the at least four cyclodextrin moieties and each of the at least four comonomers alternate in the water soluble linear polymer conjugate. 128. The pharmaceutical composition of claim 124, wherein the therapeutic agent is an anti-neoplastic agent. 129. The pharmaceutical composition of claim 125, wherein the therapeutic agent is an anti-neoplastic agent. 130. The pharmaceutical composition of claim 126, wherein the therapeutic agent is an anti-neoplastic agent. 131. The pharmaceutical composition of claim 127, wherein the therapeutic agent is an anti-neoplastic agent.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (123)
Ekwuribe Nnochiri ; Ramaswamy Muthukumar ; Rajagopalan Jayanthi Sethuraman, Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same.
Winkler, James L.; Fodor, Stephen P. A.; Buchko, Christopher J.; Ross, Debra A.; Aldwin, Lois; Modlin, Douglas N., Combinatorial strategies for polymer synthesis.
Low Philip Stewart (West Lafayette IN) Horn Mark Alan (Piscataway NJ) Heinstein Peter Frederick (West Lafayette IN), Composition and method for tumor imaging.
Curiel David T. (Chapel Hill NC) Birnstiel Max L. (Vienna ATX) Cotten Matthew (Vienna ATX) Wagner Ernst (Langenzersdorf ATX) Zatloukal Kurt (Vienna ATX) Plank Christian (Vienna ATX) Oberhauser Berndt, Composition for introducing nucleic acid complexes into higher eucaryotic cells.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Composition useful for in vivo delivery of biologics and methods employing same.
Wolff, Jon A.; Hagstrom, James E.; Monahan, Sean D.; Budker, Vladimir; Rozema, David B.; Slattum, Paul M., Compositions and methods for drug delivery using amphiphile binding molecules.
Zemel Haya (Des Plaines IL) Koch Mark B. (Des Plaines IL) Rohrbach Ronald P. (Des Plaines IL), Crosslinked cyclodextrins supported on porous refractory inorganic oxides.
Weltrowski, Marek; Morcellet, Michel; Martel, Bernard, Cyclodextrin polymers and/or cyclodextrin derivatives with complexing properties and ion-exchange properties and method for the production thereof.
Soon-Shiong Patrick (Los Angeles CA) Desai Neil P. (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Heintz Roswitha A. (Los Angeles CA) Sojomihardjo Soebianto (Pasadena CA), Gel compositions prepared from crosslinkable polysaccharides, polycations and/or lipids and uses therefor.
Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA) Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA), Large scale photolithographic solid phase synthesis of an array of polymers.
Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA) Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA), Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof.
Vgtle Friedrich (St. Augustin DEX) Dix Johannes P. (Bonn-Beuel DEX) Jaworek Dieter (Weilheim DEX), Ligands assayed by host molecules including cyclophanes, crown ethers, crypstands and podands.
Phillips Christopher P. (Brandamore PA) Snow Robert A. (West Chester PA), Lyophilized polyethylene oxide modified protein and polypeptide complexes with cyclodextrin.
Wahlig Helmut (Darmstadt DEX) Dingeldain Elvira (Dreieich DEX) Braun Dietrich (Darmstadt-Arheilgen DEX), Medicinally useful, shaped mass of collagen resorbable in the body.
Wahlig Helmut (Darmstadt DEX) Dingeldein Elvira (Dreieich DEX) Braun Dietrich (Darmstadt DEX), Medicinally useful, shaped mass of collagen resorbable in the body.
Rhett L. Affleck ; Doug Hobbs ; Ilya Feygin ; Gregory L. Kirk ; James A. Connelly ; Ning Zhao ; James P. Mueller ; Peter Kieselbach, Method and apparatus for controlled photoelution.
Wu George Y. (Bloomfield CT) Wu Catherine H. (Bloomfield CT), Method for the introduction of genes into mammalian cells by a soluble molecular complex comprising a receptor ligand an.
Toda Fumio (Ehime JPX) Tanaka Koichi (Matsuyama JPX) Nakata Tetsuya (Ibaraki JPX), Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound.
Davis,Mark E.; Gonzalez,Hector; Hwang,Suzie (Sue Jean), Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network.
Desai Neil P. (Los Angeles CA) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Tsuchiyama Yukio (Yokohama JPX) Sato Michikatsu (Fujisawa JPX) Yagi Yoshiaki (Fujisawa JPX) Ishikura Tomoyuki (Chigasaki JPX), Partially methylated cyclodextrins and process for producing the same.
Casey Donald J. (Ridgefield CT) Huffman Kenneth R. (Stamford CT), Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same.
Hyon Suong-Hyu (Uji JPX) Ikada Yoshita (Uji JPX), Polylactic acid type microspheres containing physiologically active substance and process for preparing the same.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Desai, Neil P.; Tao, Chunlin; Yang, Andrew; Louie, Leslie; Yao, Zhiwen; Soon-Shiong, Patrick; Magdassi, Shlomo, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Colin Michel (Thoiry FRX) Guenard Daniel (Montrouge FRX) Gueritte-Voegelein Francoise (Paris FRX) Potier Pierre (Paris FRX), Taxol derivatives, their preparation and pharmaceutical compositions containing them.
Bachmann Frank (Freiburg DEX) Lohmann Dieter (Munchenstein CHX) Chabrecek Peter (Basel CHX), Unsaturated carbohydrate derivatives polymers thereof and their use.
Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA) Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA), Very large scale immobilized polymer synthesis.
Szejtli Jzsef (Budapest HUX) Fenyvesi va (Budapest HUX) Zsadon Bla (Budapest HUX) Szilasi Mria (Budapest HUX) Dcsei Lajos (Budapest HUX), Water soluble cyclodextrin polymers substituted by ionic groups and process for the preparation thereof.
Nussstein Peter (Munich DEX) Staudinger Guenther (Munich DEX) Kreuzer Franz-Heinrich (Martinsried DEX) Schmitt-Sody Wolfgang (Wolfratshausen DEX), Water-insoluble cyclodextrin polymers and processes for their preparation.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.